Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Insurance covers it but excludes Wegovy
Tail fin is darkly mottled
Backed by science and driven by real results, its time to meet the next chapter in feeling good in your body and loving it along the way
GLP-1s account for 8% of all US prescriptions GLP-1 RA prescribing has reached a new milestone, with nearly 8% of all prescriptions in March 2026 attributed to these therapies following the largest quarter-over-quarter percentage point increase in overall GLP-1 RA prescribing observed since the study began in 2019
Compounding market transition (Feb 6, 2026): The FDA announced a major enforcement action specifically targeting "mass-marketed" compounded GLP-1 alternatives
US$ 23.23
US$ 28.87
US$ 22.41
US$ 20.35
US$ 21.80
US$ 29.80
US$ 20.54
US$ 27.90
